Fig. 3

The equilibrium between NET biomarkers and DNase1 or DNase1L3 antigens is disrupted in severe patients. A–D Comparison of the quantity of DNase1 protein (A) and the ratios between NET biomarkers [MPO-DNA (B), H3cit (C), H3cit-DNA (D)] and DNase1 antigen among non-severe (n = 32), severe (n = 15), and critical COVID-19 patients (n = 37). Results are expressed as fold change in comparison to healthy donors (n = 7) and fold change ratio. E–H Comparison of the quantity of DNase1L3 protein (E) and the ratios between NET biomarkers [MPO-DNA (F), H3cit (G), and H3cit-DNA (H)] and DNase1L3 antigen among non-severe (n = 32), severe (n = 15), and critical (n = 37) COVID-19 patients. Results are expressed as fold change in comparison to healthy donors (n = 7) and fold change ratio. Statistical analyses were conducted using a Compound Poisson-Gamma model adjusted for age, sex and BMI